High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment

BACKGROUND: SLFN11 was reported to be a predictive marker for DNA damage drugs. The study was to investigate whether SLFN11 expression is related to sensitivity to adjuvant oxaliplatin-based treatment in colorectal cancer. METHODS: A tissue microarray, made with specimens from consecutive 261 patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Yanhong, Cai, Yue, Huang, Yan, Yang, Zihuan, Bai, Yang, Liu, Yanlu, Deng, Xiuping, Wang, Jianping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631086/
https://www.ncbi.nlm.nih.gov/pubmed/26525741
http://dx.doi.org/10.1186/s12885-015-1840-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631086/
https://www.ncbi.nlm.nih.gov/pubmed/26525741
http://dx.doi.org/10.1186/s12885-015-1840-6

Ejemplares similares